Soleno Therapeutics Files 8-K
Ticker: SLNO · Form: 8-K · Filed: Aug 18, 2025 · CIK: 1484565
| Field | Detail |
|---|---|
| Company | Soleno Therapeutics Inc (SLNO) |
| Form Type | 8-K |
| Filed Date | Aug 18, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, 8-k
TL;DR
SOLENO filed an 8-K, standard compliance stuff.
AI Summary
On August 18, 2025, Soleno Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No specific financial figures or material events were detailed in the provided excerpt.
Why It Matters
This filing indicates Soleno Therapeutics is complying with regulatory reporting requirements, which is standard practice for publicly traded companies.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for regulatory compliance and does not appear to disclose any new material information or risks.
Key Players & Entities
- SOLENO THERAPEUTICS INC (company) — Registrant
- Capnia, Inc. (company) — Former Company Name
- 100 Marine Parkway, Suite 400 Redwood City, CA 94065 (location) — Principal Executive Offices Address
FAQ
What is the primary purpose of this 8-K filing for Soleno Therapeutics, Inc.?
The primary purpose of this 8-K filing is for Regulation FD Disclosure and to report Financial Statements and Exhibits.
What is Soleno Therapeutics, Inc.'s principal executive office address?
Soleno Therapeutics, Inc.'s principal executive office is located at 100 Marine Parkway, Suite 400, Redwood City, CA 94065.
What was Soleno Therapeutics, Inc.'s former company name?
Soleno Therapeutics, Inc.'s former company name was Capnia, Inc.
On what date was this 8-K report filed?
This 8-K report was filed on August 18, 2025.
What is the Standard Industrial Classification (SIC) code for Soleno Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for Soleno Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 503 words · 2 min read · ~2 pages · Grade level 12.4 · Accepted 2025-08-18 06:54:43
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value SLNO NASDAQ Indicate by
Filing Documents
- d69752d8k.htm (8-K) — 24KB
- d69752dex991.htm (EX-99.1) — 25KB
- g69752ex99_1s10g1.jpg (GRAPHIC) — 90KB
- g69752ex99_1s11g1.jpg (GRAPHIC) — 79KB
- g69752ex99_1s12g1.jpg (GRAPHIC) — 79KB
- g69752ex99_1s13g1.jpg (GRAPHIC) — 81KB
- g69752ex99_1s14g1.jpg (GRAPHIC) — 71KB
- g69752ex99_1s15g1.jpg (GRAPHIC) — 56KB
- g69752ex99_1s16g1.jpg (GRAPHIC) — 70KB
- g69752ex99_1s17g1.jpg (GRAPHIC) — 48KB
- g69752ex99_1s18g1.jpg (GRAPHIC) — 64KB
- g69752ex99_1s19g1.jpg (GRAPHIC) — 82KB
- g69752ex99_1s1g1.jpg (GRAPHIC) — 45KB
- g69752ex99_1s20g1.jpg (GRAPHIC) — 53KB
- g69752ex99_1s21g1.jpg (GRAPHIC) — 44KB
- g69752ex99_1s2g1.jpg (GRAPHIC) — 133KB
- g69752ex99_1s3g1.jpg (GRAPHIC) — 77KB
- g69752ex99_1s4g1.jpg (GRAPHIC) — 102KB
- g69752ex99_1s5g1.jpg (GRAPHIC) — 49KB
- g69752ex99_1s6g1.jpg (GRAPHIC) — 58KB
- g69752ex99_1s7g1.jpg (GRAPHIC) — 64KB
- g69752ex99_1s8g1.jpg (GRAPHIC) — 78KB
- g69752ex99_1s9g1.jpg (GRAPHIC) — 92KB
- 0001193125-25-182184.txt ( ) — 2259KB
- slno-20250818.xsd (EX-101.SCH) — 3KB
- slno-20250818_lab.xml (EX-101.LAB) — 18KB
- slno-20250818_pre.xml (EX-101.PRE) — 11KB
- d69752d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Corporate Presentation 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SOLENO THERAPEUTICS, INC. Date: August 18, 2025 By: /s/ Anish Bhatnagar Anish Bhatnagar Chief Executive Officer